(0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Hotel Grand Majestic Plaza

Mar 10, 2016 8:00 AM - Mar 11, 2016 5:00 PM

Truhlarska 16, 110 00 Prague 1, Czech Republic

Benefit/Risk Management

Enjoy a comprehensive and practical training in designing benefit/risk management systems using current, as well as new, regulatory tools.

Overview

This intensive course explores current opportunities made possible by the legislation, advances in information technology and a new scientific methodology to enhance and modernise the approaches in the product lifecycle management.

The course starts with the current regulatory thinking about the benefit/risk methodology, including the relevant project of the European Medicines Agency (EMA) / Committee for Medicinal Products for Human Use (CHMP). It gives a basis for the second part of the course, exploring the new European benefit/risk management planning - a notion stemming from the experience gathered over five years with the EU Risk Management Plans (EU-RMPs). Participants will learn how to take advantage of the efficacy follow-up options given by both the European Paediatric Regulation and the Advanced Therapies Regulation. A practical training in drafting key aspects of the regulatory submissions is included.

Although a lot of things may be planned and controlled, there are always unforeseen scenarios. The last part of the course will help participants to deal with the most dangerous ones – when the benefit/risk of the product is suddenly affected by emerging information. Participants will be trained on how to deal with such a situation, using the most effective techniques in risk communication and media crisis management.

90% of attendees would recommend the course. (2015 attendee survey)

CONTINUING EDUCATION

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom has accredited this training course with CPD credits.
The Swiss Association of Pharmaceutical Professionals (SwAPP) and the Swiss Society for Pharmaceutical Medicine (SGPM) have accredited this training course with 11.5 credits.
DIA is an authorised training organiation accredited under the number 11 99 53383 75 to the Préfet of Ile-de-France.

What participants from previous course say:
"The best part of the programme are the real examples, practical questions and most importantly the exercises that make attendees live the situation and force them to go through interesting situations"
"The course was excellent"

What you will learn

  • New legal possibilities for benefit optimisation and risk minimisation of products in the EU
  • Designing benefit/risk management systems using current regulatory tools, including: EU Risk Management Plans (EU-RMPs), Risk Evaluation and Mitigation Strategies (REMS), Development Safety Update Report (DSUR), Periodic Safety Update Report (PSUR), Follow-Up Measures (FUMs), and potentially EU Benefit Risk Management Plan (EU-BRMP)
  • Choice of effectiveness of study design for safety and efficacy follow-up
  • How to manage a media, legal and regulatory crisis

Who should attend?

Professionals most likely to benefit from this training have 2-5 years of experience in regulatory affairs, risk management, pharmacovigilance, drug safety, medical affairs or similar positions within the pharmaceutical industry. Those charged with the design and maintenance of risk management systems, Qualified Persons for Pharmacovigilance (QPPVs) and heads of benefit/risk management, patient safety, or lifecycle management will find all the necessary information and skills needed for successful benefit/risk management.

Learning objectives

At the conclusion of this course, participants will be able to:

  • Describe safety, efficacy, and effectiveness profiles of drugs
  • Plan safety and efficacy follow-up systems, including the best choice of study designs and available registries
  • Optimise benefits and minimise risks of products, including the best use of an evidence-based toolbox
  • Present the first three bullet points to key regulatory authorities and health technology assessment bodies
  • Measure effectiveness of the planned actions – both risk minimisation and benefit optimisation
  • Save the product if things go wrong and benefit-risk seems negative

Participants will complete a knowledge check at the end of the course and will be provided with feedback to ensure learning objectives are attained.

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.